Please find enclosed the Unaudited Financial Results for the Quarter ended 30th June 2026.

Ref No.: ZLL/CS/BM/BSE-NSE Date: 06.08.2026 BSE Limited, National Stock Exchange of India Limited, Compliance Department, Listing Compliance Department, P. J. Towers, Dalal Street, Exchange Plaza, Bandra-Kurla Complex, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 (Scrip Code - 541400) (Symbol - ZIMLAB) Dear Sir, Sub : Outcome of Board Meeting held on 06.08.2026 Ref : Notice of Board Meeting dt. 31.07.2026 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors in their meeting held today, 06th August, 2026 have inter-alia, considered and approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended 30th June, 2026. Copy of the Unaudited Financial Results (Consolidated and Standalone) along with the Limited Review Report issued by Deloitte Haskins & Sells LLP, Statutory Auditors of the Company is enclosed herewith. Kindly take the intimation on record. The Board Meeting commenced at 10:30 a.m. (IST) and concluded at 01:50 p.m. (IST) Thanking you, Yours faithfully, For ZIM LABORATORIES LIMITED (Piyush Nikhade) Company Secretary and Compliance Officer Membership No. A38972 Encl: as above ZIM LABORATORIES LIMITED www.zimlab.in I info@zimlab.in I CIN : L99999MH1984PLC032172 Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square, Maharashtra, India. Ph. + 91.7118.271370 I Fax : +091.7118.271470 Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960 INDEPENDENT AUDITOR’S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF ZIM LABORATORIES LIMITED 1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of ZIM LABORATORIES LIMITED (“the Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”) for the quarter ended 30 June 2026 (“the Statement”) being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“the Listing Regulations”). 2. This Statement, which is the responsibility of the Parent’s Management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent’s personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. The Statement includes the results of the following entities: Name of the Company Relationship ZIM Laboratories Limited, India Parent Company ZIM Laboratories FZE, Sharjah Subsidiary Company ZIM Health Technologies Limited, India Subsidiary Company SIA ZIM Laboratories Limited, Latvia Subsidiary Company ZIM Thinorals Private Limited, India Subsidiary Company ZIMTAS PTY Limited, Australia Subsidiary Company ZIM Scientific Office LLC, Dubai Step-Down Subsidiary 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. For DELOITTE HASKINS & SELLS LLP Chartered Accountants (Firm’s Registration No. 117366W/W-100018) Viral R. Shah Partner (Membership No.117654) (UDIN: 26117654YSGOIG3110) Place: Mumbai Date: 06 August 2026 ZIM Laboratories Limited Registered Office : Sadoday Gyan(Ground Floor),Opp.NADT,Nelson Square Nagpur - 440013, Maharashtra, India CIN:L99999MH1984PLC032172, Website: www.zimlab.in STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 JUNE 2026 (Rs. in lakhs, unless otherwise stated) Quarter ended Year ended Sr. No. Particulars 30 June 2026 31 March 2026 30 June 2025 31 March 2026 (Unaudited) (Unaudited) (Unaudited) (Audited) Refer Note 3 1 Income a) Revenue from operations 9,417.85 10,527.34 7,175.61 3 7,440.01 b) Other income 99.23 616.21 147.63 1 ,138.30 Total income 9,517.08 11,143.55 7,323.24 3 8,578.31 2 Expenses a) Cost of materials consumed 4,381.61 4,970.37 2,761.73 1 6,404.76 b) Purchases of stock-in-trade 50.91 235.96 159.30 7 46.83 c) Changes in inventories of finished goods and work-in-progress (485.87) (493.83) 79.86 ( 614.14) d) Employee benefits 1,918.37 1,739.15 1,461.27 6 ,390.38 e) Finance costs 364.34 331.03 330.35 1 ,320.23 f) Depreciation and amortisation 537.22 510.29 486.35 1 ,997.80 g) Other expenses 3,307.80 3,356.41 2,287.58 1 1,511.17 Total expenses 10,074.38 10,649.38 7,566.44 3 7,757.03 3 Profit /(loss) before tax (1-2) (557.30) 494.17 (243.20) 8 21.28 4 Tax expense /(credit) Current Tax 0.02 181.78 8.72 3 42.39 Deferred Tax (155.62) (61.60) (64.43) ( 104.92) Total tax expense /(credit) (155.60) 120.18 (55.71) 2 37.47 5 Net Profit /(loss) after tax (3-4) (401.70) 373.99 (187.49) 5 83.81 6 Other comprehensive income a) Items that will not be reclassified to profit or loss (3.46) 43.12 (18.99) ( 13.85) b) Tax (expense)/credit on the items that will not be reclassified to profit or loss 1.01 (12.56) 5.53 4 .03 c) Items that may be reclassified to profit or loss 39.40 19.07 55.35 2 20.49 d) Tax (expense)/credit on the items that will be reclassified to profit or loss - - - - Other comprehensive income (net of tax) 36.95 49.63 41.89 2 10.67 7 Total comprehensive income /(loss) (5+6) (364.75) 423.62 (145.60) 7 94.48 8 Net Profit /(loss) after tax attributable to Owners (401.68) 373.98 (187.49) 583.81 Non-controlling interest (0.02) 0.01 - - 9 Other comprehensive income attributable to Owners 36.95 49.63 41.89 2 10.67 Non-controlling interest - - - - 10 Total comprehensive income /(loss) attributable to Owners (364.73) 423.61 (145.60) 794.48 Non-controlling interest (0.02) 0.01 - - 11 Paid-up equity share capital (face value of Rs. 10/- each) 5,354.90 5,350.03 4,872.58 5,350.03 12 Other equity (revaluation reserve : Rs. Nil) 2 4,265.33 13 Earnings per share (face value of Rs. 10/- each) (not annualised for the quarters) (Rs.) Basic (0.75) 0.76 (0.38) 1 .19 Diluted (0.75) 0.76 (0.38) 1 .19 Notes : 1)TheabovestatementofconsolidatedfinancialresultsofZIMLaboratoriesLimited('theParent'or'theCompany')anditssubsidiaries(togetherreferred toas'Group')werereviewedandrecommendedbytheAuditCommitteeandapprovedbytheBoardofDirectorsattheirrespectivemeetingsheldon05 August 2026 and 06 August 2026. The above results have been subjected to limi [Showing first 8,000 characters — download PDF for full document]